$236.22-1.70 (-0.71%)
Cardinal Health, Inc.
Cardinal Health, Inc. in the Healthcare sector is trading at $236.22 with a market capitalization of $45.9B. Wall Street consensus targets $245.27 (15 analysts), implying a +3.8% move over the next 12 months. The stock is currently near its 52-week high of $240.93, remaining 18.6% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $60.94B↓ | $65.63B↑ | $64.01B↑ | $60.16B↑ | $54.88B |
| Gross Profit | $2.50B↑ | $2.40B↑ | $2.32B↑ | $2.20B↑ | $2.12B |
| Operating Income | $842.00M↑ | $763.00M↑ | $754.00M↑ | $585.00M↓ | $656.00M |
| Net Income | $399.00M↓ | $467.00M↑ | $450.00M↑ | $239.00M↓ | $506.00M |
Cardinal Health, Inc. operates as a healthcare services and products company in the United States and internationally. It operates in two segments: Pharmaceutical and Specialty Solutions, and Global Medical Products and Distribution. The company prov...
Cardinal Health (CAH) closed at $237.92 in the latest trading session, marking a +1.35% move from the prior day.
Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it more challenging to maintain high growth rates as they’ve already captured significant portions of their markets.
AbbVie and Pfizer are taking divergent paths to navigate patent expirations and competition. Dig into their financials, risk profiles, and valuation metrics.
Here is how Bayer Aktiengesellschaft (BAYRY) and Cardinal Health (CAH) have performed compared to their sector so far this year.
Cardinal (CAH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.